Dynamics of plasma active GLP-1 versus insulin and glucose concentrations during GLP-1 infusion in rat model of postprandial hyperglycemia

被引:4
|
作者
Eiki, Jun-ichi [1 ]
Yada, Toshihiko [2 ,3 ]
机构
[1] Banyu Pharmaceut Co Ltd, Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan
[2] Jichi Med Univ, Sch Med, Div Integrat Physiol, Dept Physiol, Shimotsuke, Tochigi 3290498, Japan
[3] Natl Inst Nat Sci, Natl Inst Physiol Sci, Div Adaptat Dev, Dept Dev Physiol, Okazaki, Aichi 4448585, Japan
基金
日本学术振兴会;
关键词
GLP-1; Insulin; Glucose; Rat; GLUCAGON-LIKE PEPTIDE-1; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; PANCREATIC BETA-CELLS; CYTOSOLIC CA2+; INCRETIN; POLYPEPTIDE; RELEASE; PEPTIDE-1-(7-36)AMIDE; MECHANISMS; SECRETION;
D O I
10.1507/endocrj.K11E-096
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In vitro studies in isolated pancreas and islets have shown that glucagon-like peptide-1 (GLP-1) promotes insulin release in a typical concentration-dependent manner. In contrast, the relationship between plasma GLP- I and insulin concentrations in vivo is complicated, because GLP-1-promoted insulin release lowers blood glucose, which influences glucose-dependent insulinotropic ability of GLP-1. GLP-1 also stimulates insulin release via hepatoportal neuronal mechanism. Hence, the dynamic relationship between plasma active GLP-1 vs. insulin and glucose concentrations is obscure. In this study, we aimed to determine in vivo relationships between these parameters in rats. To mimic postprandial state, intraduodenal glucose challenge in anesthetized rats was performed, which can minimize the release of endogenous GLP- I. The glucose challenge induced the 1st phase and 2nd phase insulin release. GLP-1 infusion from jugular vein significantly and concentration-dependently enhanced area under the curve (AUC) of the 1st phase insulin, in which the minimum effective active GLP-1 concentration was 6.6 pmol/L. In contrast, bell-shaped dose responses were observed for both the 2nd phase and total insulin AUCs, in which a significant increase was obtained only with 11 pmol/L of active GLP-1 for total insulin AUC. A statistically significant reduction in the plasma glucose AUC was observed when active GLP-1 concentration was 11 pmol/L and 21 pmol/L. These results indicate that GLP-1 markedly enhances the 1st phase insulin release while less potently the 2nd phase insulin release, possibly due to a negative feedback regulation of beta-cells via reduced plasma glucose levels by the enhanced 1st phase insulin release.
引用
收藏
页码:691 / 698
页数:8
相关论文
共 50 条
  • [21] GLP-1 Enhances Insulin Biosynthesis in Type 2 Diabetic Subjects during Hyperglycemia
    Chen, Zijian
    Jayatillake, Harsha
    Cruikshank, Greg
    Zheng, Bing Na
    Hovorka, Roman
    Rogatsky, Eduard
    Stein, Daniel T.
    DIABETES, 2011, 60 : A94 - A94
  • [22] Liraglutide and Dapagliflozin Induce an Increase in Plasma GLP-1 and GLP-2 Concentrations
    Ghanim, Husam
    Green, Kelly
    Dandona, Paresh
    DIABETES, 2019, 68
  • [23] The GLP-1 metabolite GLP-1(9-36)amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans
    Ellrichmann, M.
    Bulut, K.
    Götze, O.
    Deacon, C. F.
    Holst, J. J.
    Schmidt, W. E.
    Meier, J. J.
    REGULATORY PEPTIDES, 2006, 135 (03) : 122 - 123
  • [24] Direct effect of GLP-1 infusion on endogenous glucose production in humans
    M. Seghieri
    E. Rebelos
    A. Gastaldelli
    B. D. Astiarraga
    A. Casolaro
    E. Barsotti
    A. Pocai
    M. Nauck
    E. Muscelli
    E. Ferrannini
    Diabetologia, 2013, 56 : 156 - 161
  • [25] Direct effect of GLP-1 infusion on endogenous glucose production in humans
    Seghieri, M.
    Rebelos, E.
    Gastaldelli, A.
    Astiarraga, B. D.
    Casolaro, A.
    Barsotti, E.
    Pocai, A.
    Nauck, M.
    Muscelli, E.
    Ferrannini, E.
    DIABETOLOGIA, 2013, 56 (01) : 156 - 161
  • [26] Effect of GIP and GLP-1 antagonists on insulin release in the rat
    Tseng, CC
    Zhang, XY
    Wolfe, MM
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1999, 276 (06): : E1049 - E1054
  • [27] The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia
    Novodvorsky, Peter
    Haluzik, Martin
    CURRENT ATHEROSCLEROSIS REPORTS, 2022, 24 (01) : 13 - 21
  • [28] The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia
    Peter Novodvorský
    Martin Haluzík
    Current Atherosclerosis Reports, 2022, 24 : 13 - 21
  • [29] Plasma FGF21 concentrations are regulated by glucose independently of insulin and GLP-1 in lean, healthy humans
    Solomon, Thomas P. J.
    Carter, Steven
    Haus, Jacob M.
    Karstoft, Kristian
    von Holstein-Rathlou, Stephanie
    Nielsen, Mette S.
    Gillum, Matthew P.
    PEERJ, 2022, 10
  • [30] Endogenously released GLP-1 is not sufficient to alter postprandial glucose regulation in the dog
    Kathryn M. S. Johnson
    Tiffany Farmer
    Kathleen Schurr
    E. Patrick Donahue
    Ben Farmer
    Doss Neal
    Alan D. Cherrington
    Endocrine, 2011, 39 : 229 - 234